At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells in MS. [WATCH TIME: 6 minutes]
At CMSC 2026, the director of the multiple sclerosis research unit at Ottawa Hospital discussed how integrating clinical research into MS practice enhances clinician expertise. [WATCH TIME: 5 minutes]
The professor of neurology and neuroscience at Johns Hopkins University School of Medicine discussed the ongoing debate around animal models in neuropathy research, the rise of iPSC-derived systems, and why he believes both approaches are needed going forward.
A sleep specialist and sleep patient advocate discussed diagnostic and patient-reported outcome measures that aim to better capture the cognitive, functional, and psychosocial burden of central disorders of hypersomnolence.
Matthew Evans, BM, BCh, DPhil, a consultant neurologist at the University of Oxford, discusses the diagnostic approach to small fiber neuropathy and the challenges of confirming immune-mediated disease. [WATCH TIME: 3 minutes]
The professor of neurology at Wake Forest School of Medicine discussed the evolution of sleep medicine education, its relevance across neurologic specialties, and advice for early-career clinicians.
Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.
At ATMRD 2026, a neurologist at UCLA discussed the growing recognition of demoralization in Parkinson disease, highlighting how it differs from depression and apathy and outlining strategies to help patients maintain resilience, purpose, and quality of life. [Watch time: 5 minutes]
The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]
The professor of neuroscience at the University of Cambridge discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.
The associate professor at Johns Hopkins University discussed emerging biomarkers outside of neurofilament light chain, including muscle MRI, immune-targeted markers, and microRNA research in peripheral nerve disorders. [WATCH TIME: 3 minutes]
The associate clinical professor at the University of South Carolina School of Medicine discussed data presented at SLEEP 2026 from a phase 2 study of orexin 2 receptor agonist alixorexton in narcolepsy type 2. [WATCH TIME: 3 minutes]
Matthew Evans, BM, BCh, DPhil, consultant neurologist at Imperial College Healthcare NHS Trust, discusses emerging evidence for immune-mediated small fiber neuropathy, current diagnostic challenges, and the need for better clinical trials and biomarkers.
Maya Hrachova, DO, neurologist and neuro-oncologist at Allina Health Brain and Spine Institute, discusses the evolving role of neurologic consultation in cancer care and the importance of accurate diagnosis in complex oncology patients.
The phase 3 REVITALYZ study assessed whether once-nightly extended-release sodium oxybate can improve excessive daytime sleepiness and other core symptoms of idiopathic hypersomnia.
The professor of neurology and pediatrics at Vanderbilt University Medical Center discussed her advocacy for sleep health, especially for pediatric patients and their families, at SLEEP 2026. [WATCH TIME: 5 minutes]
The FDA indicated that 3-year phase 1/2 data may support a BLA submission for AMT-130, an investigational gene therapy that previously demonstrated significant slowing of Huntington disease progression in treated patients.
AT ATMRD 2026, the CEO and founder of Yes, and... X discussed why social connection and support groups should be viewed as critical components of Parkinson disease care, alongside traditional medical management. [WATCH TIME: 3 minutes]
The section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed new evidence-based guidelines for sleep-disordered breathing in hospitalized patients.
Long-term phase 3 extension data showed that pitolisant was generally well tolerated and associated with sustained improvements in excessive daytime sleepiness, sleep inertia, and functional outcomes in adults with idiopathic hypersomnia for more than 2 years.
The phase 3 EMNERGIZE study evaluates whether the complement C2 inhibitor empasiprubart can improve disability and functional outcomes in adults with chronic inflammatory demyelinating polyneuropathy.
At SLEEP 2026, the section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed the high burden of undiagnosed sleep apnea in hospitalized patients. [WATCH TIME: 5 minutes]
Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.
A preclinical study found that SP16, an LRP1 agonist, reduced mechanical hypersensitivity and cold hyperalgesia in paclitaxel-treated mice in an LRP1-dependent manner, implicating Schwann cell LRP1 as a potential therapeutic target in CIPPN.
A randomized, placebo-controlled study will assess whether weekly subcutaneous imeroprubart can reduce relapse risk in patients with chronic inflammatory demyelinating polyneuropathy despite standard-of-care treatment.
New phase 2 data showed that riliprubart was associated with sustained improvements in patient-reported outcomes at 76 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
The MAGNAZ trial, the first study evaluating zanubrutinib added to rituximab in anti-MAG polyneuropathy, reported baseline characteristics of 32 enrolled patients at PNS 2026, with efficacy results to follow.
Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, discussed the current landscape of biomarkers in peripheral nerve disorders and the evolving role of neurofilament light chain in clinical care and research. [WATCH TIME: 3 minutes]
Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.
A real-world comparative study found efgartigimod produced similar GBS disability score improvement to plasma exchange at 4 weeks, with significantly greater MRC sum score recovery at weeks 8 and 12, and a comparable safety profile.
